DRKS00025316
Completed
Not Applicable
Immunogenicity according to reactogenicity of Covid-19 vaccines
niversitätsklinikum Regensburg0 sites90 target enrollmentMay 12, 2021
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversitätsklinikum Regensburg
- Enrollment
- 90
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •o minimum age 18 years
- •o two doses of BNT 162b2 at intervals of 3\-6 weeks o 2nd dose 4\-10 weeks before enrolment
- •o informed consent
Exclusion Criteria
- •o no informed consent
- •o no willingness to complete the survey
- •o no history of covid\-19
Outcomes
Primary Outcomes
Not specified
Similar Trials
Enrolling By Invitation
Not Applicable
Follow-up: Immunogenicity according to reactogenicity of Covid-19 vaccinesReactogenicity and immunogenicity of ComirnatyDRKS00026982niversity Medical Center Regensburg76
Not yet recruiting
Phase 4
Mixing of COVID vaccines studyCTRI/2021/08/035648Christian Medical College
Recruiting
Phase 4
Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2prevention covidDRKS00025271niklinik Regensburg Abteilung für Hygiene und Infektiologie154
Active, not recruiting
Phase 1
The 6-in-1 Vaccine StudyEUCTR2018-003451-38-GBClinical Trials and Research Governance (CTRG)240
Active, not recruiting
Not Applicable
Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects greater than or equal to 18 and less than or equal 60 years and elderly subjects greater than or equal to 61 years of age. - Influvac annual update 2006Prophylaxis of influenza, especially in those who run an increased risk of associated complications.EUCTR2006-001300-37-DESolvay Pharmaceuticals B.V.120